Literature DB >> 34314056

2020 guidelines for the diagnosis and treatment of prurigo.

Takahiro Satoh1, Hiroo Yokozeki2, Hiroyuki Murota3, Yoshiki Tokura4, Kenji Kabashima5, Kenji Takamori6, Tetsuo Shiohara7, Eishin Morita8, Setsuya Aiba9, Yumi Aoyama10, Takashi Hashimoto1, Ichiro Katayama11.   

Abstract

Prurigo is a treatment-resistant skin disease characterized by multiple isolated papules/nodules that cause severe itch. Prurigo papules/nodules occur either as primary lesions or as secondary lesions due to persistent scratching. The fundamental concepts and classifications of prurigo have not been sufficiently established, and considerable confusion remains regarding this topic. Clinical guidelines for chronic prurigo in Japan were published in 2012 in an attempt to reduce confusion regarding the concepts of prurigo and to standardize laboratory tests and treatments. However, the diagnostic terms for prurigo and associated concepts have changed over time, and new forms of treatment are under development. We have, thus, updated and revised the guidelines to classify prurigo based on clinical forms and causes, and disease name classifications based on the clinical form have been further simplified, such as prurigo nodularis, prurigo chronica multiformis, and prurigo (not otherwise specified). Expressions for acute, subacute, and chronic forms are not used. These guidelines outline the current concepts and specify treatments for prurigo.
© 2021 Japanese Dermatological Association.

Entities:  

Keywords:  classifications; prurigo chronica multiformis prurigo nodularis; prurigo not otherwise specified; treatments

Year:  2021        PMID: 34314056     DOI: 10.1111/1346-8138.16067

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  1 in total

1.  Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study.

Authors:  Yu-Ri Woo; Sehee Wang; Kyung-Ah Sohn; Hei-Sung Kim
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.